Evaxion Biotech A/S announced on July 17, 2026, that it will present three-year follow-up data from its Phase 2 clinical trial of EVX-01 in melanoma at the upcoming European Society for Medical Oncology (ESMO) Congress. The data release is the first long-term durability readout for the company's AI-designed personalized cancer vaccine. It follows initial trial results showing a 12-month objective response rate of 38% in combination with Merck's Keytruda. The market will scrutinize whether those responses persist beyond three years, a critical threshold for vaccine-based oncology assets.
Context — why this matters now
The cancer vaccine sector faces a high bar for proof after high-profile setbacks. GSK and CureVac terminated their COVID-19 vaccine collaboration in 2025, redirecting resources to oncology. Merck and Moderna's mRNA-4157 (V940) showed a 49% reduction in death or recurrence risk for melanoma in 2023, but five-year survival data is still pending. Moderna's stock rose 8% on the day of that Phase 2 readout. The current macro backdrop for small-cap biotech is challenging, with the SPDR S&P Biotech ETF (XBI) trading near its 2025 lows. Short interest in pre-revenue immunology firms averages 12% of float. The ESMO presentation represents a binary catalyst for Evaxion. The company's valuation hinges on demonstrating that its AI immunotherapy platform can generate durable clinical responses, validating a capital-intensive development path.
Multiple firms are racing to prove long-term benefit. BioNTech's FixVac platform reported a 44% three-year survival rate in a Phase 1 melanoma study in 2024. Gritstone bio reported a median overall survival of 14.5 months for its GRANITE vaccine in colorectal cancer in February 2026. The failure of Bavarian Nordic's prostate cancer vaccine in 2025 erased $400 million in market cap in a single session. The sector needs a clear durability win to restore investor confidence in personalized vaccine approaches. Evaxion's data arrives at a pivotal moment for funding and partnership discussions.
Data — what the numbers show
The initial EVX-01 Phase 2 trial enrolled 42 patients with advanced melanoma. The primary endpoint was objective response rate at 12 months. The combination of EVX-01 and pembrolizumab (Keytruda) achieved a 38% ORR. The control arm of pembrolizumab alone showed a 19% ORR. The three-year data will report overall survival, progression-free survival, and duration of response.
| Metric | Initial 12-Month Data (2025) | 3-Year Benchmark (BioNTech 2024) |
|---|
| Objective Response Rate | 38% | 44% |
| Median PFS | 9.1 months | 11.6 months |
| 3-Year Survival Rate | Not Reported | 44% |
The biotech firm's market capitalization stands at approximately $65 million as of July 2026. It holds $28 million in cash and equivalents, with a quarterly cash burn rate of $6.5 million. This implies a runway of about four quarters without additional financing. Evaxion's stock (EVAX) has a 52-week range of $0.85 to $3.20. Peer BioNTech (BNTX) trades at a $22 billion market cap, while Moderna (MRNA) holds a $38 billion valuation. Evaxion's data needs to show a three-year survival rate above 40% to be considered competitive. Anything below 30% would likely be viewed as a clinical failure.
Analysis — what it means for markets / sectors / tickers
Strong durability data would benefit the entire neoantigen vaccine sector. Primary beneficiaries include BioNTech (BNTX), Moderna (MRNA), and Gritstone bio (GRTS). These firms would see reduced regulatory risk for their own late-stage programs. Suppliers like Charles River Laboratories (CRL) and Lonza Group (LONN.SW) would see increased demand for manufacturing services. Weak data would have the opposite effect, strengthening the position of dominant checkpoint inhibitors like Merck's (MRK) Keytruda and Bristol Myers Squibb's (BMY) Opdivo. It would also shift focus toward cell therapies from Gilead Sciences (GILD) and Novartis (NVS).
A key limitation is the trial's small sample size. With only 42 patients, statistical power is limited. The open-label design also introduces potential bias. The counter-argument is that durable responses in even a subset of late-stage melanoma patients represent a meaningful advance. Success is not defined by beating a large statistical threshold but by showing clear signals of long-term benefit where checkpoint inhibitors alone often fail. Trading flow data shows increased options volume in EVAX for August 2026, with a concentration at the $2.50 strike price. Short interest remains elevated at 15% of the float, indicating skepticism. A positive data shock could trigger a significant short squeeze, similar to the 120% move in Gritstone bio shares after its February 2026 data release.
Outlook — what to watch next
Immediate focus shifts to the ESMO Congress presentation date and the subsequent full data publication in a peer-reviewed journal. The next major catalyst for Evaxion is the initiation of a Phase 3 trial, which requires partnership funding. Investors will watch for a strategic collaboration announcement with a large pharma firm by Q4 2026. For the broader sector, watch Moderna and Merck's Phase 3 trial of mRNA-4157 (V940), with an expected data readout in late 2027. BioNTech's Phase 3 trial of BNT111 in melanoma has a primary completion date in 2028.
Key levels to watch for Evaxion's stock are the $1.00 Nasdaq listing compliance threshold and the 200-day moving average near $1.75. A sustained break above $2.50 on high volume would signal renewed institutional interest. For the XBI ETF, a break above the $85 resistance level could signal a broader biotech rally if the data is positive. Conversely, a failure to hold the $78 support level would indicate continued sector-wide risk aversion. Partnership terms will be a critical gauge; an upfront payment exceeding $50 million would validate the platform, while a milestone-heavy deal with minimal upfront cash would signal weak partner conviction.
Frequently Asked Questions
What is a personalized cancer vaccine like EVX-01?
A personalized cancer vaccine is designed for an individual patient based on the unique mutations, or neoantigens, found in their tumor. Evaxion uses its AI platform, PIONEER, to analyze a patient's tumor DNA sequence. The platform predicts which neoantigens are most likely to trigger a potent immune response. A vaccine is then manufactured containing these targets to teach the patient's immune system to recognize and attack cancer cells. This differs from traditional vaccines, which are identical for all patients targeting shared pathogens.
